Xi'an Yangsen IL-12 and IL-23 inhibitors Starno ® (Usnu mono-anti-injection) are available in China

Recently, johnson andcompany(http://in ChinaPharmaceutical(http://subsidiary Xi'an Yangsen Pharmaceutical Co., Ltdannounced that its all-human source "double-target" leukocyte interleukin 12 (IL-12) and leukocyte interleukin 23 (IL-23) inhibitor Sedano ® (STELARA ®), or Usnu mono-injection, has been listed in ChinaOn The Hdano ®
Starno ® is an innovative dosing model -- a biologic that is injected every three months during the maintenance period to treat severe and severe plaque in adults that are not responsive to other systems such as cyclosporine, methotrexate (MTX) or PUVA (rehydration and UVA) Patients with psoriasis patients,The cytano ® is targeted against IL-12 and IL-23, the p40 protein subunit commonly found in IL-12 and IL-23 is specificly bound to inhibit these two cytokines that play a key role in the occurrence and development of psoriasisstudies
two randomized, double-blind, placebo-controlled Phase III clinicaltrials in 1996 patients(http://PHOENIX 1 and PHOENIX 2 showed that Thedano ® long-term efficacy, maintenance of skin damage removal and improvement in quality of life for up to 5 yearsanother Phase III clinical trial of Chinese group LOTUS showed that 82.5% (132/60) of patients using Theidano ® reached paSI75, the main endpoint of the trial, at 12 weeks, and 11.1% in the placebo groupSignificant improvements were also made in all critical secondary endpoints, including the reach of PASI90 at 28 weeks in patients using Theidano ®PHOENIX Extended Extended Study 4 shows that Starno ® can maintain a clinical treatment response to psoriasis for a long time, and no dose-related or cumulative toxicity has been observed as Theidano ® treatment time is extendedThe Real World PSOLAR study, which included data from more than 12,000 patients using Starno ® and other treatment options over an eight-year period, was consistent with the overall safety of Starno ®in addition,, several real-world registered studies have shown that the totaldrug(http://retention rate and lower risk of discontinuation are higher in the totaldrug(http:// of the Starnor ® than other biologics included in the study